Resistance to human immunodeficiency virus type 1 protease inhibitors.
about
In vitro antiviral activity of the novel, tyrosyl-based human immunodeficiency virus (HIV) type 1 protease inhibitor brecanavir (GW640385) in combination with other antiretrovirals and against a panel of protease inhibitor-resistant HIVLack of synergy for inhibitors targeting a multi-drug-resistant HIV-1 proteaseViability of a drug-resistant human immunodeficiency virus type 1 protease variant: structural insights for better antiviral therapyBMS-232632, a highly potent human immunodeficiency virus protease inhibitor that can be used in combination with other available antiretroviral agentsStructural and kinetic analyses of the protease from an amprenavir-resistant human immunodeficiency virus type 1 mutant rendered resistant to saquinavir and resensitized to amprenavirIn vitro resistance profile of the human immunodeficiency virus type 1 protease inhibitor BMS-232632ACTG (AIDS Clinical Trials Group) 384: a strategy trial comparing consecutive treatments for HIV-1Altered substrate specificity of drug-resistant human immunodeficiency virus type 1 protease.Impact of distal mutations on the network of coupled motions correlated to hydride transfer in dihydrofolate reductase.Susceptibility of the porcine endogenous retrovirus to reverse transcriptase and protease inhibitorsPopulation genetic analysis of the protease locus of human immunodeficiency virus type 1 quasispecies undergoing drug selection, using a denaturing gradient-heteroduplex tracking assay.Functional correlates of insertion mutations in the protease gene of human immunodeficiency virus type 1 isolates from patients.Genotypic testing for human immunodeficiency virus type 1 drug resistance.Atazanavir signature I50L resistance substitution accounts for unique phenotype of increased susceptibility to other protease inhibitors in a variety of human immunodeficiency virus type 1 genetic backbonesHIV-1 protease has a genetic T-cell adjuvant effect which is negatively regulated by proteolytic activityEmergence of drug resistance mutations in human immunodeficiency virus type 2-infected subjects undergoing antiretroviral therapyA novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1A bacteriophage lambda-based genetic screen for characterization of the activity and phenotype of the human immunodeficiency virus type 1 proteaseComparison of human immunodeficiency virus type 1 Pr55(Gag) and Pr160(Gag-pol) processing intermediates that accumulate in primary and transformed cells treated with peptidic and nonpeptidic protease inhibitorsShort-term measures of relative efficacy predict longer-term reductions in human immunodeficiency virus type 1 RNA levels following nelfinavir monotherapy.Comprehensive bioinformatic analysis of the specificity of human immunodeficiency virus type 1 protease.Gag non-cleavage site mutations contribute to full recovery of viral fitness in protease inhibitor-resistant human immunodeficiency virus type 1.Catalytic efficiency and vitality of HIV-1 proteases from African viral subtypes.Polymorphism and drug-selected mutations in the protease gene of human immunodeficiency virus type 2 from patients living in Southern France.The Genetic Basis of HIV-1 Resistance to Reverse Transcriptase and Protease Inhibitors.Design and synthesis of stereochemically defined novel spirocyclic P2-ligands for HIV-1 protease inhibitorsHuman immunodeficiency virus type 1 protease-correlated cleavage site mutations enhance inhibitor resistance.Susceptibility to PNU-140690 (Tipranavir) of human immunodeficiency virus type 1 isolates derived from patients with multidrug resistance to other protease inhibitors.Human immunodeficiency virus type 1 protease cleavage site mutations associated with protease inhibitor cross-resistance selected by indinavir, ritonavir, and/or saquinavir.Retracing the evolutionary pathways of human immunodeficiency virus type 1 resistance to protease inhibitors: virus fitness in the absence and in the presence of drug.Emergence of resistance to protease inhibitor amprenavir in human immunodeficiency virus type 1-infected patients: selection of four alternative viral protease genotypes and influence of viral susceptibility to coadministered reverse transcriptase n
P2860
Q24672993-1003FADE-6D3A-4798-B66E-3D480A4256DBQ27637329-3BF786F7-527F-489C-8825-FB1DAB41BB01Q27640250-62F3EB76-20F5-4A6C-85A4-C2EEF1FD21A2Q28344472-132ADD97-F3A9-4EE4-99FB-43029BD13844Q28344511-D91EA404-D817-4AEE-BE36-B7DB2ADCF788Q28344594-C332D130-FB23-4BF3-A6BF-34EF4B9FD4CDQ28362780-516861F9-BA38-479C-A0BE-8874F155B148Q31033895-29C21A84-CEE1-4FE4-9761-1B2A23D18BD7Q33784331-E58A7593-DB95-4DE1-8EA5-B1FBACC9A2B4Q33835882-C48F6C9F-6620-4EDD-BFB1-FD2EBC6D4AA4Q33843999-10AB59C4-A1C3-4213-A6B9-81511B940F1DQ33849423-8EF7BB42-951F-44B3-AA40-30B2E499CB3AQ33906239-1A28758F-FC2A-44A7-A239-049B91734D97Q33935276-2E3F5D4A-CE17-4304-911E-2B3AE5114BEEQ33964165-F4CF3E8B-7F4B-42B7-AB0D-221FB212A5D6Q33966329-19FBDA10-6282-4507-A7E3-A35BC1912A07Q33979107-CDB46EE7-4070-4868-8FAB-2762B07277EDQ33979321-20989613-8C97-488F-A988-26261E86B93AQ33979580-60F2AD0B-D0BC-4788-BF39-C84E9043BF94Q33982056-E5DDF12B-623F-459E-98A8-4D1C01FA275CQ33984365-4CCABAB1-893E-4516-9DC7-85CAAB717CE1Q35548279-2B12EEBE-54CB-4C16-B6C3-69FA4D29304CQ35927934-DAEB0202-D177-4BAE-B696-823D11563651Q36239954-25283191-AE27-4689-A632-0D2E8E0FAD19Q37018369-65BA10F1-595F-47C3-903E-84AC832EC15DQ37350487-C6810EC4-E7D5-447B-AD61-5522B96942CDQ37410823-F1AB3E14-802D-45BB-99DB-231C7B4781C9Q39473811-4A2EE587-ED9C-4658-987B-18232ED6573EQ39601382-C6F6AAC2-3841-4D6F-9A6B-089885B6CF22Q39612306-580D6AB8-7F3C-4C1B-B67A-E4ECA18EF63AQ39653073-7272844D-C7E8-4040-866D-A4E5C6593623
P2860
Resistance to human immunodeficiency virus type 1 protease inhibitors.
description
1998 nî lūn-bûn
@nan
1998年の論文
@ja
1998年論文
@yue
1998年論文
@zh-hant
1998年論文
@zh-hk
1998年論文
@zh-mo
1998年論文
@zh-tw
1998年论文
@wuu
1998年论文
@zh
1998年论文
@zh-cn
name
Resistance to human immunodeficiency virus type 1 protease inhibitors.
@en
Resistance to human immunodeficiency virus type 1 protease inhibitors.
@nl
type
label
Resistance to human immunodeficiency virus type 1 protease inhibitors.
@en
Resistance to human immunodeficiency virus type 1 protease inhibitors.
@nl
prefLabel
Resistance to human immunodeficiency virus type 1 protease inhibitors.
@en
Resistance to human immunodeficiency virus type 1 protease inhibitors.
@nl
P2860
P356
P1476
Resistance to human immunodeficiency virus type 1 protease inhibitors
@en
P2093
P2860
P304
P356
10.1128/AAC.42.11.2775
P407
P577
1998-11-01T00:00:00Z